Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

Blood Adv. 2023 Jun 27;7(12):2884-2887. doi: 10.1182/bloodadvances.2022008990.

Authors

Constantine S Tam¹, Judith Trotman^{2

3}, Stephen Opat^{4

5}, Jennifer C Stern⁶, Heather Allewelt⁶, Kunthel By⁶, William Novotny⁶, Jane Huang⁶, Alessandra Tedeschi⁷

Affiliations

¹ The Alfred Hospital, Monash University, Melbourne, VIC, Australia.
² Concord Repatriation General Hospital, Concord, NSW, Australia.
³ The University of Sydney, Concord, NSW, Australia.
⁴ Monash Health, Clayton, VIC, Australia.
⁵ Monash University, Clayton, VIC, Australia.
⁶ BeiGene, San Mateo, CA.
⁷ ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Hairy Cell* / drug therapy
Piperidines / therapeutic use
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use

Substances

zanubrutinib
Piperidines
Pyrazoles
Pyrimidines